Latest
19:33
【CSPC Pharmaceutical (01093.HK): Paliperidone Palmitate Injection Approved for Marketing; Indicated for Schizophrenia Acute and Maintenance Treatment】NewTimeSpace News: CSPC Pharmaceutical (1093.HK) announced on July 24 that its self-developed second-generation antipsychotic long-acting injectable Paliperidone Palmitate Injection (specifications: 75mg, 100mg, 150mg) has been approved for marketing by the NMPA, indicated for the acute and maintenance phases of schizophrenia. The product requires monthly dosing only without oral supplementation, has been listed in authoritative treatment guidelines including the Chinese Guidelines for the Prevention and Treatment of Schizophrenia (2025 Edition), and its approval will further enrich the Group's psychiatric and neurological product portfolio.
Tag:
CSPC PHARMA01093.HK
19:15
19:14
17:24
【Fosun Pharma (02196.HK): DM1001 Preparation Obtains Clinical Trial Approval】NewTimeSpace News: Fosun Pharma announced on July 24 that its controlling subsidiary Fosun Wanbang received approval from the National Medical Products Administration (NMPA). The DM1001 preparation is authorized for clinical trials targeting signs and symptoms of idiopathic Parkinson's disease in adults, with Phase I clinical trials planned to be carried out in China once conditions permit.
Tag:
FOSUN PHARMA02196.HK